Influenza and other respiratory viruses · 2023
Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination-A prospective multicentre cohort of health professionals (SURPRISE study).
Многоцентровое исследованиеСтатьяПоддержка правительства СШАПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kohler Philipp, Babouee Flury Baharak, Güsewell Sabine, Egger Thomas, Leal Onicio, Brucher Angela, Lemmenmeier Eva, Meier Kleeb Dorette, Möller J Carsten, Ortner Manuela, Rieder Philip, Ruetti Markus, Schmid Hans-Ruedi, Stocker Reto, Vuichard-Gysin Danielle, Speer Oliver, Wiggli Benedikt, Besold Ulrike, McGeer Allison, Risch Lorenz, Friedl Andrée, Schlegel Matthias, Vernazza Pietro, Kahlert Christian R, Kuster Stefan P, SURPRISE Study Group
Аннотация
The effects of different types of pre-existing immunity on the frequency of clinical symptoms caused by the SARS-CoV-2 breakthrough infection were prospectively assessed in healthcare workers during the Omicron period. Among 518 participants, hybrid immunity was associated with symptom reduction for dizziness, muscle or limb pain and headache as compared to vaccination only. Moreover, the frequencies of dizziness, cough and muscle or limb pain were lower in participants who had received a booster vaccine dose. Thus, hybrid immunity appeared to be superior in preventing specific symptoms during breakthrough infection compared to vaccination alone. A booster vaccine dose conferred additional symptom reduction.